Zobrazeno 1 - 4
of 4
pro vyhledávání: '"L. B Polushkina"'
Autor:
T. N. Subbotina, I. E. Maslyukova, A. A. Faleeva, P. A. Nikolaeva, A. S. Khazieva, E. A. Dunaeva, K. O. Mironov, L. B. Polushkina, I. S. Martynkevich, S. V. Vereshchagina, B. V. Barankin
Publikováno v:
Онкогематология, Vol 15, Iss 2, Pp 85-91 (2020)
Background. There are problems related to both quantitative assessment of an allele burden level of a mutant gene and interpretation of results in DNA samples with the burden level of the mutant allele less than 15–20 %, when using Sanger sequencin
Externí odkaz:
https://doaj.org/article/bc3b0376a2864fffaa914ecdf25e92fa
Autor:
A. A. Zhernyakova, I. S. Martynkevich, V. A. Shuvaev, L. B. Polushkina, M. S. Fominykh, V. Yu. Udal’eva, I. I. Zotova, D. I. Shiсhbabaeva, S. V. Voloshin, S. S. Бессмельцев, A. V. Chechetkin, K. M. Abdulkadyrov
Publikováno v:
Онкогематология, Vol 12, Iss 2, Pp 30-38 (2017)
Background. Thrombosis and hemorrhage are the main category of complications, that affects the overall survival (OS), quality of life and therapy option choice in essential thrombocythemia (ET). Molecular marker presence (JAK2V617F (JAK2+), MPL (MPL+
Externí odkaz:
https://doaj.org/article/ff4d08c63d6c4263aec7f738cf2269b0
Autor:
M. S. Fominykh, V. A. Shuvaev, I. S. Martynkevich, L. B. Polushkina, V. Yu. Udal’eva, K. M. Abdulkadyrov
Publikováno v:
Онкогематология, Vol 11, Iss 2, Pp 37-39 (2016)
Patients with myelofibrosis in blast-phase commonly have a median overall survival of only 3–6 months. Given the older median age of onset and heavy pretreatment, intensive chemotherapy often is not appropriate and has low efficacy with high toxici
Externí odkaz:
https://doaj.org/article/7eb709681d9f4452b8452457999d58aa
Autor:
A. M Radzhabova, S. V Voloshin, I. S Martynkevich, A. A Kuzyaeva, VA. Shuvaev, E. V Motyko, A. Y Kuvshinov, M. S Fominykh, A. V Schmidt, L. B Polushkina, M. P Bakay, S. A Tiranova, M. N Zenina, N. A Potihonova, SA. Kudryashova, V. A Balashova, J. V Chubukina, O. S Uspenskaya, E. V Karyagina, A. N Bogdanov, A. V Chechetkin
Publikováno v:
Genes & Cells. 14:55-61
Detection of FLT3 gene mutations in acute myeloid leukemia is now recognized as an unfavorable factor that affects the disease course, emerging the risk of relapses and overall survival shortening and disease-free survival of patients. The aim of the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4af4b36307e43e7d49984a402281ca53
https://doi.org/10.23868/201903007
https://doi.org/10.23868/201903007